Saturday 17 October 2026
Export PLRX’s income statement to Excel — free account
Pliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.
0.90
0.07
−7.22%
Follow PLRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (50.29%) | (53.62%) | (61.55%) | (64.27%) |
+8 more TTM periods Free account |
|
| (37.69%) | (41.37%) | (48.01%) | (48.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(61.91%) | (67.70%) | (81.60%) | (75.55%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.14) | (1.59) | (2.09) | (2.58) | |
Free Cash Flow |
(70.62) | (98.56) | (128.55) | (158.64) | |
Capital Expenditures |
0.27 | 0.15 | (0.22) | (0.43) | |
| Other line items | |||||
Cash ROIC |
(23.15%) | (29.33%) | (34.54%) | (33.57%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | (61.11) | (57.14) | |
Operating CF/Net income |
0.77 | 0.87 | 0.86 | 0.90 | |
Depreciation/Fixed assets |
0.92 | 1.70 | 1.92 | 1.39 | |
Capex/Depreciation |
0.12 | 0.03 | (0.04) | (0.07) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.14) | (1.60) | (2.09) | (2.58) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates